Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
Steady: 0 in the last 7 days
Updated sep 25
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Fate Therapeutics, based in San Diego, is seeking support for an accelerated regulatory pathway from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Fate Therapeutics announced from its operational base that it is targeting the U.S. market for clinical trials.Sub-event
Fate Therapeutics seeks accelerated regulatory pathway support from the FDA.1 source
Keep exploring
The entities involved
-
Fate Therapeutics
a clinical-stage biopharmaceutical company in San Diego, United States
Nothing else this week.
- FDA
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Expertise is guiding drug development toward regulatory approval, involving the FDA and David Rubenstein.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA policy proposal affects the operations of AI, Inc.
- NIH is funding research conducted by the National Cancer Institute (NCI) toward an FDA Investigational New Drug (IND) application.